Low and Declining Rate of 4-Class ARV Resistance Among Treatment-Experienced Patients in the EuResist Database

March 8-11, 2020; Boston, Massachusetts
Analysis of the EuResist database reveals prevalence and predictors of resistance to all 4 main ARV drug classes in treatment-experienced patients in Europe.
Format: Microsoft PowerPoint (.ppt)
File Size: 158 KB
Released: March 15, 2020

Acknowledgements

Provided by USF Health, in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Gilead Sciences
ViiV Healthcare

Related Content

Expert selections of important HIV data from IDWeek 2021, including current and investigational ART, HIV PrEP, and metabolic outcomes of ART.

Eric S. Daar, MD Darcy Wooten, MD Released: October 19, 2021

Clinical Care Options (CCO) and Dr. Josep Llibre: Perspective on the landscape of ART options for highly treatment-experienced patients with HIV

Josep M. Llibre, MD, PhD Released: October 18, 2021

Dr William Short and Clinical Care Options (CCO): Data fails to support adding agents to intensify ART, switching ART, or adding IL-2 for patients with suboptimal CD4+ cell counts on suppressive ART

William R. Short, MD, MPH, AAHIVS Released: October 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue